 |
|
|
|
|
|
WRITTEN COVERAGE STARTS THURSDAY FEB 13 |
|
|
|
|
|
|
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
|
|
|
|
|
|
Clarity to Present COBRA and CLARIFY Abstracts at Two World-Leading Conferences
|
|
|
|
|
|
Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting
|
|
|
|
|
|
Thursday, February 13, 2025
|
|
|
|
| Oral Abstract Session A: Prostate Cancer - 8:00 AM - 9:40 AM
|
|
|
|
|
Radical Prostatectomy Versus Radiotherapy in High-Risk Prostate Cancer: Emulated Randomized Comparison with Individual Patient Data from Two Phase III Randomized Trials
Presented By: Soumyajit Roy, MBBS
|
|
|
|
|
Gene Signature Predictor of Dose-Response to Prostate Radiation: Validation of PORTOS in Phase III Trials
Presented By: Shuang Zhao, MD
|
|
|
|
|
Which Patients with Metastatic Hormone-Sensitive Prostate Cancer Benefit More from Androgen Receptor Pathway Inhibitors? STOPCAP Meta-Analyses of Individual Participant Data
Presented By: David John Fisher, MSc
|
|
|
|
|
Final Overall Survival with Talazoparib + Enzalutamide as First-Line Treatment in Unselected Patients with Metastatic Castration-Resistant Prostate Cancer in the Phase 3 TALAPRO-2 Trial
Presented By: Neeraj Agarwal, MD, FASCO
|
|
|
|
|
|
|
| Understanding Radioligand Therapies for Advanced Prostate Cancer - 10:10 AM - 11:25 AM
|
|
|
|
|
PSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing
Presented By: Louise Emmett, MD, MBChB, FRACP
Beyond PSMA-Targeted Agents for Advanced Disease Presented By: William Kevin Kelly, DO
Seeing Is Believing: Radiographic Criteria to Assess Response
Presented By: Danny Mena Cortes
Association of Baseline and On-Treatment ctDNA Fraction with Clinical Outcomes in Patients with mCRPC in the PSMAfore Study of 177Lu-PSMA-617.
Presented By: Johann S. De Bono, MD, PhD, FRCP
|
|
|
|
|
|
|
|
|
|
|
|
| Rapid Oral Abstract Session A: Prostate Cancer - 5:00 PM - 5:45 PM
|
|
|
|
|
Mevrometostat (PF-06821497), an Enhancer of Zeste Homolog 2 Inhibitor, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Dose-Expansion Study.
Presented By: Michael Thomas Schweizer, MD
|
|
|
|
|
Impact of Testosterone Recovery After Androgen Deprivation Therapy on Overall Survival in Patients with High-Risk Prostate Cancer: Long-Term Data from a Phase III Trial
Presented By: Abdenour Nabid, MD
|
|
|
|
|
Gut Health and Prostate Cancer: The Influence of a Specific Phytochemical-Rich Food Capsule plus or Minus a Probiotic/prebiotic Blend on Symptoms and progression—A Randomised, Double-Blind Placebo-Controlled Trial
Presented By: Robert J. Thomas, MD
|
|
|
|
|
A High Omega-3, Low Omega-6 Diet with Fish Oil for Men with Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.
Presented By: William Aronson, MD
|
|
|
|
|
Transdermal Oestradiol Patches as Androgen Deprivation Therapy: Efficacy and Safety of Combining with Androgen Receptor Pathway Inhibitors in Metastatic Prostate cancer—Randomised Comparison from the STAMPEDE Trial Platform
Presented By: Nicholas James, PhD, FRCP, MBBS
|
|
|
|
|
Metastases-Directed Therapy in Addition to Standard Systemic Therapy in Oligometastatic Castration Resistant Prostate Cancer: A Randomized Phase II Trial (GROUQ-PCS 9)
Presented By: Tamim M Niazi, MDCM, FRCPC
|
|
|
|
|
|
Friday, February 14, 2025
|
|
|
|
| Poster Session A: Prostate Cancer - 11:45 AM - 12:45 PM
|
|
|
|
|
Darolutamide Monotherapy in Patients with Castration-Sensitive Prostate Cancer (CSPC) After Biochemical Recurrence (BCR): ARAMON Lead-in Phase Results
Presented By: Andrew Laccetti, MD, MS
|
|
|
|
|
Darolutamide plus ADT in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) by Disease Volume: Subgroup Analysis of the Phase 3 ARANOTE Trial
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
|
|
| Poster Session B: Prostate Cancer - 11:30 AM - 12:45 PM
|
|
|
|
|
Real-World Outcomes of Nadofaragene Firadenovec in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Presented By: Jacob A. Moyer, BS
|
|
|
|
|
|
|
| The ABCs of ADCs: Unleashing the Power of Antibody-Drug Conjugates in Advanced Bladder Cancer - 12:45 PM-2:00 PM |
|
|
|
|
Targeting Bladder Cancer With Antibody Drug Conjugates
Presented By: Di Maria Jiang, MD, MSc, FRCPC
|
|
|
|
|
HER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer
Presented By: Funda Meric-Bernstam, MD, FASCO
|
|
|
|
|
Overcoming Challenges of Antibody-Drug Conjugate Toxicity in Bladder Cancer
Presented By: Daniel Castellano, MD
|
|
|
|
|
Better Together? Exploring Novel Drug Combinations With Antibody-Drug Conjugates
Presented By: Terence W. Friedlander, MD
|
|
|
|
|
Nectin-4 Targeted ADC, SHR-A2102, in Patients with Advanced or Metastatic Urothelial Carcinoma: A Phase 1 Study
Presented By: Bixia Tang
|
|
|
|
|
|
|
| Panning for Gold: The Role of ctDNA as a Biomarker for Bladder Cancer - 2:30 PM - 3:45 PM |
|
|
|
|
Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?
Presented By: Roger Li, MD
|
|
|
|
|
Evolution of ctDNA Detection with Next Generation Technology
Presented By: Alexander Wyatt, PhD
|
|
|
|
|
Potential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer
Presented By: Nimira S. Alimohamed, FRCPC
|
|
|
|
|
Beneath the Surface: Unleashing the Potential of Ctdna across the Spectrum of Urothelial Carcinoma
Presented By: Gillian Vandekerkhove, PhD, MSc
|
|
|
|
|
|
Saturday, February 15, 2025
|
|
|
|
| Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers - 7:10 AM - 8:10 AM
|
|
|
|
|
First-in-Human Phase 0 Safety, Imaging, Pharmacokinetics, and Dosimetry Study of 64Cu-PD-32766, a Carbonic Anhydrase IX (CAIX)-Targeting Peptide, in Patients with Clear Cell Renal Cell Carcinoma (ccRCC).
Presented By: Toshihiro Horii, PhD
|
|
|
|
|
|
|
| Oral Abstract Session C: Renal Cell Cancer - 8:10 AM - 9:45 AM |
|
|
|
|
KEYMAKER-U03 Substudy 03B: Pembrolizumab and Targeted Therapy Combinations for Advanced ccRCC
Presented By: Katy Beckermann, MD, PhD
Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma: Final Follow-up Results from the CheckMate 9ER Trial
Presented By: Robert J. Motzer, MD
Prospective COTRIMS (Cologne Trial of Retroperitoneal Lymphadectomy in Metastatic Seminoma) Trial: Final Results
Presented By: Axel Heidenreich, MD
Cabozantinib in Combination with Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma: Final Results of COSMIC-313
Presented By: Laurence Albiges, MD, PhD
|
|
|
|
|
|
|
|
|
|
|
|
| Rapid Oral Abstract Session C: Renal Cell Cancer - 12:45 PM - 1:30 PM |
|
|
|
|
EPIC-A: Phase II Trial of Cemiplimab plus Standard of Care Chemotherapy Followed by Maintenance Cemiplimab in Locally Advanced or Metastatic Penile Carcinoma.
Presented By: Amit Bahl, MD, FRCP, FRCR
|
|
|
|
|
Casdatifan Monotherapy in Patients with Previously Treated Clear Cell Renal Cell Carcinoma: Safety, Efficacy and Subgroup Analysis Across Multiple Doses from ARC-20, a Phase 1 Open-Label Study.
Presented By: Toni Choueiri, MD, FASCO
|
|
|
|
|
Racial Disparities in Renal Cell Carcinoma Histology and Outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).
Presented By: Xiaofan Lu, PhD
|
|
|
|
|
Lenvatinib plus Tislelizumab as First-Line Therapy for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Single-Center, Single-Arm, Phase II Study
Presented By: Wen Kong, PhD
|
|
|
|
|
Final Overall Survival and New ctDNA Analysis in MET-Driven Advanced Papillary Renal Cancer (CALYPSO).
Presented By: Francesca Jackson-Spence, MBChB
|
|
|
|
|
